Regeneron Pharmaceuticals Inc.

Operating company

HQ: United States

Total cases

9 (1 active)

Claimant-side

Respondent-side

Regeneron Pharmaceuticals Inc. has been party to nine Unified Patent Court cases, 4 times as claimant and 5 times as respondent. The most recent on record is UPC CFI 2221/2025 at the Munich Central Division, brought by Amgen Inc. Its most recent decision on the merits was in UPC CoA 529/2024 at the Court of Appeal on 25 November 2025: patent upheld as granted.

Top opponents

Amgen Inc.7

More opponents

Top firms

Bardehle Pagenberg8

More firms

Start 14-day free trialEvery opponent and every firm acting for and against Regeneron Pharmaceuticals Inc..Already a user? Sign in

Recent cases

View all cases

2025-12-23UPC CFI 2221/2025Munich CD—Amgen Inc. v Regeneron Pharmaceuticals Inc.
2025-07-11UPC CoA 646/2025Court of AppealWithdrawnAmgen NV v Regeneron Pharmaceuticals Inc.
2025-02-28UPC CFI 195/2025Dusseldorf LDWithdrawnSanofi Biotechnology SAS v Amgen Inc.
2024-09-13UPC CoA 529/2024Court of AppealPatent upheld as grantedAmgen Inc. v Regeneron Pharmaceuticals Inc.
2024-05-03CC 24999/2024Dusseldorf LDPatent upheld as grantedAmgen S.R.L. v Regeneron Pharmaceuticals Inc.
2024-01-10UPC CFI 505/2023Dusseldorf LDNo infringementSanofi Biotechnology SAS v Amgen Inc.
2023-11-10CC 586764/2023Munich CDPatent revokedRegeneron Pharmaceuticals Inc. v Amgen Inc.
2023-09-13UPC CoA 320/2023Court of AppealProcedural onlySanofi-Aventis Deutschland GmbH v Amgen Inc.
2023-06-26UPC CFI 14/2023Munich LDProcedural onlyAmgen Inc. v Sanofi-Aventis Deutschland GmbH